Aptose Biosciences Q1 EPS $(0.73) Beats $(0.74) Estimate
Portfolio Pulse from Benzinga Newsdesk
Aptose Biosciences reported Q1 EPS of $(0.73), surpassing the consensus estimate of $(0.74) by 1.35%. This marks a significant improvement from last year's Q1 losses of $(2.25) per share.
May 14, 2024 | 8:01 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Aptose Biosciences reported a smaller loss than expected for Q1, with EPS of $(0.73) against estimates of $(0.74), indicating a significant year-over-year improvement.
Beating EPS estimates typically generates positive investor sentiment, suggesting potential short-term upward price movement. The significant year-over-year improvement in losses further strengthens the case for a positive outlook.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100